MICRO-HOPE

MICRO-HOPE

Microalbuminuria, Cardiovascular and Renal Outcomes—Heart Outcomes Prevention Evaluation. A HOPE substudy which found that ramipril reduces macro- and microvascular complications of hypertensive patients with diabetes. MICRO-HOPE concluded that the ramipril-treated group had a 22% to 37% reduction in progression to overt nephropathy, acute MI, stroke, and cardiovascular death.

MICRO-HOPE

Cardiology A HOPE substudy–Microalbuminuria, Cardiovascular & Renal Outcomes–Heart Outcomes Prevention Evaluation–that found that ramipril prevents macro- and microvascular complications of hypertensive Pts with DM. See HOPE.
Mentioned in ?
References in periodicals archive ?
Previously unpublished results of MICRO-HOPE (Microalbuminuria, Cardiovascular, and Renal Outcomes in the Heart Outcomes Prevention Evaluation), a prospective substudy within the landmark HOPE study, failed to show any benefit for 400 IU of vitamin E per day over placebo for the prevention of microvascular complications in 3,654 randomized patients with diabetes mellitus.
Vitamin E also failed to have any impact on cardiovascular events in diabetic participants in MICRO-HOPE or in nondiabetic subjects with cardiovascular disease who were randomized to receive vitamin E in the larger HOPE trial.
Vitamin E was studied in HOPE and MICRO-HOPE because results of the Physicians' Health Study, the Nurses' Health Study, and other observational studies suggested that ingesting more than 100 IU of vitamin E per day reduces the risk of cardiovascular disease.